Structures of Marburgvirus Glycoprotein and Its Complex with NPC1 Receptor

Why It Matters

These insights explain Marburgvirus's extreme lethality and provide concrete structural templates for antivirals and vaccines, filling a critical gap in filovirus countermeasures.

Key Takeaways

• First resolved structures of Marburg GP alone and with NPC1
• MBV GP mediates entry hundreds‑fold more efficiently than EBOV
• NPC1 binds RAVV GP with ~11‑fold higher affinity than EBOV
• Glycan cap loop blocks NPC1 but not nanobody binding
• Nanobody Nanosota‑MB1 neutralizes RAVV by picomolar affinity

Pulse Analysis

Marburgvirus remains one of the deadliest filoviruses, yet it lacks approved vaccines or therapeutics. By focusing on the viral glycoprotein, the primary driver of host‑cell entry, researchers have addressed a long‑standing blind spot in pandemic preparedness. The new cryo‑EM maps of RAVV GP, both in its native cleaved form and when engaged with the endosomal receptor NPC1, illuminate how subtle structural variations can dramatically alter infectivity, offering a roadmap for rational drug design.

The structural comparison with Ebola GP uncovers a unique three‑loop engagement of NPC1, anchored by a repositioned glycan‑cap loop that partially shields the receptor‑binding site. This configuration not only boosts binding affinity—approximately eleven times stronger than Ebola’s interaction—but also triggers pronounced conformational shifts that loosen GP protomer packing, priming the virus for membrane fusion. Such mechanistic clarity explains why Marburg GP drives entry efficiencies that dwarf those of EBOV, a factor that likely contributes to its higher case‑fatality rate.

Beyond basic science, the discovery of nanobody Nanosota‑MB1, which binds the cleaved GP with picomolar strength, opens a promising therapeutic avenue. Nanobodies are small, stable, and amenable to engineering, making them attractive candidates for antiviral cocktails or as scaffolds for vaccine immunogen design. Coupled with the detailed structural templates now available, pharmaceutical efforts can accelerate the development of entry inhibitors, antibody‑based therapies, and next‑generation vaccines, strengthening global health defenses against future Marburg outbreaks.